In our clinical and in vivo studies, we showed the usefulness of serum IL-6 as a surrogate marker for evaluating the prognosis and efficacy of anti-IL-6 receptor antibody as a mediator of cancer cachexia. This evidence concerns the gene IL6 and cancer.